A detailed history of Prudential Financial Inc transactions in Kodiak Sciences Inc. stock. As of the latest transaction made, Prudential Financial Inc holds 79,108 shares of KOD stock, worth $419,272. This represents 0.0% of its overall portfolio holdings.

Number of Shares
79,108
Previous 79,108 -0.0%
Holding current value
$419,272
Previous $185,000 11.35%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.29 - $4.48 $87,249 - $170,688
38,100 Added 92.91%
79,108 $185,000
Q1 2024

May 14, 2024

BUY
$3.01 - $7.45 $30,701 - $75,990
10,200 Added 33.11%
41,008 $215,000
Q3 2023

Nov 13, 2023

SELL
$1.8 - $7.49 $449,550 - $1.87 Million
-249,750 Reduced 89.02%
30,808 $55,000
Q2 2023

Aug 11, 2023

SELL
$4.3 - $9.48 $418,820 - $923,352
-97,400 Reduced 25.77%
280,558 $1.94 Million
Q1 2023

May 12, 2023

BUY
$4.81 - $8.88 $761,182 - $1.41 Million
158,250 Added 72.03%
377,958 $2.34 Million
Q4 2022

Feb 14, 2023

BUY
$6.52 - $8.05 $54,116 - $66,815
8,300 Added 3.93%
219,708 $0
Q3 2022

Nov 04, 2022

SELL
$7.57 - $12.5 $146,858 - $242,500
-19,400 Reduced 8.41%
211,408 $1.64 Million
Q2 2022

Aug 15, 2022

BUY
$5.04 - $9.48 $1.16 Million - $2.19 Million
230,808 New
230,808 $1.76 Million
Q1 2022

May 13, 2022

SELL
$7.09 - $89.45 $22,893 - $288,834
-3,229 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$80.85 - $128.49 $89,015 - $141,467
-1,101 Reduced 25.43%
3,229 $415,000
Q3 2021

Nov 15, 2021

BUY
$81.97 - $106.94 $35,329 - $46,091
431 Added 11.05%
4,330 $445,000
Q2 2021

Aug 16, 2021

BUY
$77.2 - $126.54 $5,018 - $8,225
65 Added 1.7%
3,899 $363,000
Q1 2021

May 12, 2021

BUY
$110.45 - $164.47 $79,744 - $118,747
722 Added 23.2%
3,834 $435,000
Q4 2020

Feb 16, 2021

BUY
$60.78 - $154.03 $189,147 - $479,341
3,112 New
3,112 $457,000

Others Institutions Holding KOD

About Kodiak Sciences Inc.


  • Ticker KOD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,040,200
  • Market Cap $276M
  • Description
  • Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...
More about KOD
Track This Portfolio

Track Prudential Financial Inc Portfolio

Follow Prudential Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prudential Financial Inc with notifications on news.